Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
US Judge Dismisses Gautam Adani Criminal Charges 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Novo Nordisk A/S has finalized a groundbreaking deal to address the rising demand for its weight-loss drug, Wegovy, and diabetes treatment, Ozempic. In a significant move, Novo's largest shareholder has acquired Catalent Inc., one of the world's leading drug-manufacturing companies, for a staggering $16.5 billion, including debt.
As per Reuters, this three-way arrangement will see the Danish pharmaceutical company pay $11 billion to obtain three of Catalent's manufacturing facilities, fortifying its supply chain and overcoming recent shortages of Wegovy and Ozempic.
Fierce Competition and the Emergence of Zepbound
Novo Nordisk races to enhance its supply chain but faces fierce competition from Eli Lilly & Co. Lilly's obesity shot, Zepbound, was recently approved and is expected to become the highest-selling drug in history.
Yahoo pointed out that patient trials have demonstrated greater weight loss results with Lilly's drug compared to anything Novo has developed thus far. With this in mind, Novo's strategic acquisition of Catalent aims to solidify its market position and fend off the intensifying rivalry.
Novo Nordisk's purchase of Catalent has garnered support from Elliott Investment Management, an activist investor with a stake in the US company. The agreement values Catalent at $63.50 per share in cash, reflecting a 17% premium to its Friday closing price. However, Catalent faced manufacturing issues in September 2021, affecting its production of COVID-19 vaccines for Moderna Inc. and one of Regeneron Inc.'s top-selling drugs.
Novo Nordisk's Strategic Move to Meet Surging Demand Boosts its Market Value
Shares of Novo Nordisk have been surging alongside the increasing demand for its obesity and diabetes drugs, reaching a record high. With a market value exceeding $520 billion, Novo is now Europe's largest publicly traded company. Meanwhile, Catalent's stock rose by up to 10% in New York as news of the deal emerged.
This monumental $16.5 billion agreement between Novo Nordisk and Catalent marks the largest deal ever for companies and their controlling shareholder, Novo Holdings A/S. Novo Holdings currently controls 77% of the voting rights in the Danish drugmaker, further solidifying its influence and position in the pharmaceutical industry.
Photo: Novo Nordisk Newsroom
